Marvel Biosciences Corp. Announces Private Placement

Calgary, Alberta, Canada, May 16, 2024 - Marvel Biosciences Corp. (TSX-V: MRVL) and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively the “Company” or “Marvel”), is pleased to announce a proposed non-brokered private placement of up to 10,000,000 units (the “Units”) at a price of $0.10 per Unit for gross proceeds of up to $1,000,000 (the “Offering”). Each Unit will be...

Marvel Biosciences Share Positive Interim Results on Tau Phosphorylation with MB-204

Calgary, Alberta – March 25, 2024 – Marvel Biosciences Corp. (TSXV: MRVL OTC: MBCOF), and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively the “Company” or “Marvel”), today reported promising interim results from its acute study on MB-204 conducted by Professor Emmanuel Planel of Laval University, a world expert on Tau pathology. Tau phosphorylation is a process where...

Marvel Biosciences Announces Positive Interim Results for Autism Treatment with MB-204

Calgary, Alberta - March 12, 2024 – Marvel Biosciences Corp. (TSXV: MRVL OTC: MBCOF), and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively the “Company” or “Marvel”), today reported promising interim results from its study on MB-204, a new treatment for autism, conducted by the iBrain Institute in Tours, France. The study demonstrated that a single oral dose of MB-204 can...

Marvel Biosciences Announces Testing MB-204 on Autism by French University

Calgary, Alberta, February 20, 2024 -  Marvel Biosciences Corp. (TSXV: MRVL OTC: MBCOF) and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively the “Company“ or “Marvel“), is pleased to announce it has begun testing MB-204 in the Oprm1 mouse model of autism in collaboration with Dr. Julie Le Merrer and Dr. Jerome Becker at the iBrain Institute, Tours, France. “We are going to...

Marvel Biosciences Announces Non-Brokered Private Placement

Calgary, Alberta, Canada, January 19, 2024 - Marvel Biosciences Corp. (TSX-V: MRVL) and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively the “Company” or “Marvel”), is pleased to announce the Company has closed a non-brokered private placement (the “Offering”) of unsecured convertible debentures (each, a “Debenture”).  The closing was comprised of an aggregate of Cdn.$500,000...

Marvel Biosciences to Collaborate with Tau Expert Dr. Emmanuel Planel

Calgary, Alberta – Marvel Biosciences Corp. (TSXV: MRVL OTC: MBCOF) and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively the “Company“ or “Marvel“), is pleased to announce a collaboration with Professor Emmanuel Planel of Laval University to study the acute effect of MB-204 on Tau protein phosphorylation in mice. Abnormal tau phosphorylation is a hallmark of neurodegenerative...

Marvel Biosciences Invited to Test MB-204 on Autism by French University

Calgary, Alberta (November 16, 2023)– Marvel Biosciences Corp. (TSXV: MRVL OTC: MBCOF) and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively the “Company“ or “Marvel“), is pleased to announce a collaboration with Dr. Julie Le Merrer and Dr. Jerome Becker at iBrain Institute, Tours, France to study the effects of MB-204 in mouse models of autism. “We are very pleased to have...

Marvel Announces Successful Completion of Toxicology Study in Preparation for Phase 1 Human Trials

Calgary, Alberta (August 22, 2023)– Marvel Biosciences Corp. (TSXV: MRVL OTC: MBCOF) and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively the “Company“ or “Marvel“), is pleased to announce that it has successfully completed its 4-week good laboratory practice (GLP), FDA investigational new drug (IND), dose-ranging dog and rat studies for its lead drug candidate MB-204 paving...

Marvel Highlights Key Asset at the 2023 Alzheimer’s Association International

Calgary, Alberta – (July 10,  2023) – Marvel Biosciences Corp. (TSXV: MRVL) and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively the “Company“ or “Marvel“), is pleased to announce that it has been selected to present the Company’s scientific advancement of its key asset MB-204 titled MB-204: A Novel Adenosine A2a Antagonist for AD, ADHD and Depression at the Alzheimer's...

Marvel Successfully Completes the Dog and Rat GLP Toxicology Studies Required to Enter Human Trials

Calgary, Alberta – Marvel Biosciences Corp. (TSXV: MRVL) and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively the “Company“ or “Marvel“), is pleased to announce that it has completed the dosing portion of the 4-week good laboratory practice (GLP) FDA investigational new drug (IND) enabling dose-ranging dog and rat studies for its lead drug candidate MB-204.  “We are pleased...